Suriben, Rowena http://orcid.org/0000-0001-7971-1822
Chen, Michael
Higbee, Jared http://orcid.org/0000-0002-0522-9475
Oeffinger, Julie
Ventura, Richard http://orcid.org/0000-0001-9101-4595
Li, Betty
Mondal, Kalyani
Gao, Zhengyu
Ayupova, Dina
Taskar, Pranali http://orcid.org/0000-0001-9677-6273
Li, Diana http://orcid.org/0000-0003-1176-4228
Starck, Shelley R.
Chen, Hung-I Harry
McEntee, Michele
Katewa, Subhash D.
Phung, Van
Wang, Marilyn http://orcid.org/0000-0001-6500-3809
Kekatpure, Avantika
Lakshminarasimhan, Damodharan
White, Andre http://orcid.org/0000-0002-4393-1062
Olland, Andrea
Haldankar, Raj
Solloway, Mark J.
Hsu, Jer-Yuan
Wang, Yan
Tang, Jie
Lindhout, Darrin A.
Allan, Bernard B. http://orcid.org/0000-0002-5998-4521
Article History
Received: 27 January 2020
Accepted: 20 May 2020
First Online: 13 July 2020
Competing interests
: D.L., A.W. and A.O. declare no direct competing financial interests. All other authors are, or were, employees of NGM Biopharmaceuticals and may hold stock or stock options in this company. NGM Biopharmaceuticals, Inc. has obtained a patent, entitled “Binding proteins and methods of use thereof” (US10174119B2), that discloses protein sequences of the anti-GFRAL antibodies, GFRAL–antibody protein complexes and potential uses of those agents. J.T. and Y.W. are listed as inventors.